GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theralink Technologies Inc (OTCPK:THER) » Definitions » Forward Rate of Return (Yacktman) %

THER (Theralink Technologies) Forward Rate of Return (Yacktman) % : 0.00% (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Theralink Technologies Forward Rate of Return (Yacktman) %?

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Theralink Technologies's forward rate of return for was 0.00%.

The historical rank and industry rank for Theralink Technologies's Forward Rate of Return (Yacktman) % or its related term are showing as below:

THER's Forward Rate of Return (Yacktman) % is not ranked *
in the Biotechnology industry.
Industry Median: 4.06
* Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Theralink Technologies Forward Rate of Return (Yacktman) % Historical Data

The historical data trend for Theralink Technologies's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralink Technologies Forward Rate of Return (Yacktman) % Chart

Theralink Technologies Annual Data
Trend Feb14 Feb15 Dec16 Dec17 Dec18 Dec19 Sep20 Sep21 Sep22 Sep23
Forward Rate of Return (Yacktman) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Theralink Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Theralink Technologies's Forward Rate of Return (Yacktman) %

For the Biotechnology subindustry, Theralink Technologies's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theralink Technologies's Forward Rate of Return (Yacktman) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theralink Technologies's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where Theralink Technologies's Forward Rate of Return (Yacktman) % falls into.


;
;

Theralink Technologies Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

Theralink Technologies's Forward Rate of Return of Dec. 2023 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/0.0015+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theralink Technologies  (OTCPK:THER) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


Theralink Technologies Forward Rate of Return (Yacktman) % Related Terms

Thank you for viewing the detailed overview of Theralink Technologies's Forward Rate of Return (Yacktman) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Theralink Technologies Business Description

Traded in Other Exchanges
N/A
Address
15000 West 6th Avenue, Suite 400, Golden, CO, USA, 80401
Theralink Technologies Inc is a proteomics-based, precision medicine and molecular profiling company that specializes in patented Reverse Phase Protein Array (RPPA) and protein biomarker assay services that target multiple areas of oncology. The company provides precision oncology data through its Theralink Reverse Phase Protein Array (RPPA) assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. The firm is currently generating revenue with its multiple biopharma contracts and by testing breast cancer patients with its patented Theralink assay.
Executives
Danica Holley director 7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814
Matthew Wilson Schwartz director 15000 W. 6TH AVENUE, SUITE 400, GOLDEN CO 80401
Chilcott, Iii Thomas E. officer: Chief Financial Officer 373 INVERNESS PARKWAY, ENGLEWOOD CO 80122
Jeffrey Busch director 7373 WISCONSIN AVENUE, SUITE 800, BETHESDA MD 20814
Yvonne Fors director 1201 MONSTER RD SW STE 350, RENTON WA 98057
Michael I Ruxin director, officer: Chief Executive Officer HAEMONETICS CORPORATION INCORPORATED, 400 WOOD ROAD, BRAINTREE MA 02184
Avant Diagnostics, Inc 10 percent owner 1050 30TH STREET NW, SUITE 107, WASHINGTON DC 20007
Brian Gill Barnett officer: Chief Executive Officer 230 N SPRINGER, LOS ALTOS CA 94024
Robert Neal Holcomb director PO BOX 535, ROLLING FORK MS 39159
Volnie Carlos Fernando Alaman 10 percent owner, officer: Chief Operating Officer-Vitel MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000
Odabachian Manuel Cosme director, 10 percent owner, officer: Global Operations GM-Vitel MONTE PELVOUX 130 FLOOR 3, MEXICO O5 11000
Daniel S. Hoverman director C/O ONCBIOMUNE PHARMACEUTICALS INC.,, 11441 INDUSTRIPLEX BLVD, SUITE 190, BATON ROUGE LA 70809
Rice Charles L Jr director C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113
Andrew Albert Kucharchuk director, officer: CFO & President 549 MILGATE PLACE, BATON ROUGE LA 70810
Jonathan Frederick Head director, officer: Chief Executive Officer 6144 HAGERSTOWN DRIVE, BATON ROUGE LA 70817

Theralink Technologies Headlines

From GuruFocus

Theralink� Technologies Announces an Update on its Securities

By PRNewswire PRNewswire 10-22-2021